Seyitler Kimya Sanayi AS (SEYKM) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Seyitler Kimya Sanayi AS stock TRY 3.16, price TRY 2.39, upside +32.2%, quality 48 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.
How to read this chart
60‑month range 1.35 TRY – 7.63 TRY · fair‑value band 2.49 TRY – 4.03 TRY · the 2.39 TRY price screens below the 3.16 TRY fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 30, 2026.
Follow Seyitler Kimya Sanayi AS in your weekly email
Every Wednesday you see whether Seyitler Kimya Sanayi AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Seyitler Kimya Sanayi A.S. develops and sells medical adhesive tape products in Turkey, the Middle East, Africa, Europe, and the Americas.
Show moreShow less
The company offers surgical tapes, injection series, wound care, skin closure strip and eye pads, first aid strips, dialysis sets, heat patches, compress and swab, ointments, hemostatic series, and silicone products.
Seyitler Kimya Sanayi A.S. was incorporated in 1991 and is headquartered in Turgutlu, Turkey.
Stock analysis
Seyitler Kimya Sanayi AS (SEYKM) currently trades at 2.39 TRY, while our model-based Fair Value estimate is 3.16 TRY, implying the stock looks roughly 24.4% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 3.54 TRY per share, and 6 of the 7 models we run sit above the 2.39 TRY price.
Bear case: the Asset-Based group reads lowest at 1.70 TRY, and 1 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: 2.49 TRY (bear) to 4.03 TRY (bull), the price of 2.39 TRY sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Seyitler Kimya Sanayi AS reported revenue of 242M TRY in FY2025 versus 60.2M TRY in FY2021, a compound +41.6%/yr. Reported net income was −39.5M TRY in FY2025.
Key figures
Market cap 478M TRY (≈ $9.6M) Micro · P/E ratio 17.1 · P/S ratio 1.85 · EPS (TTM) 0.1400 TRY · Net margin 8.7% · Return on equity 4.4% · Return on assets (EBIT) 3.3% · Operating margin −15.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 65% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −42% fair-value upside, at 32%, SEYKM screens cheaper than that median.
Fair Value models
Bear2.49 TRYFair Value 3.16 TRYBull4.03 TRY
Price 2.39 TRY · Upside +32.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.1166 TRY per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.75/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−19.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.6%
Start year 2020 (pandemic). Over 10 years: +33.6% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.9% (2020) → −8.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Turkey: IMF forecast 19.3% a year to 2030, 28.5% from 2016 to 2025) that is about −18.8% a year for the price.
Compare Seyitler Kimya Sanayi AS with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 184 stocks
Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside+32.2% · Top 25%
Profitability
Return on equity (12 months)4.4% · Below median
Return on assets−6.8% · Bottom 25%
Net margin (12 months)8.7% · Above median
Operating margin (12 months)−15.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)10.8% · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Seyitler Kimya Sanayi AS Fair Value". https://www.fairvalue-calculator.com/stock/SEYKM
Frequently asked questions
Is Seyitler Kimya Sanayi AS (SEYKM) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of 3.16 TRY versus a price of 2.39 TRY, about +32% upside (undervalued).
What is the fair value of SEYKM?
Our model-based fair value for Seyitler Kimya Sanayi AS is 3.16 TRY (as of Oct 30, 2026), built from audited fundamentals. The current price: 2.39 TRY.
What is the quality score of SEYKM?
Seyitler Kimya Sanayi AS has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Seyitler Kimya Sanayi AS (SEYKM)?
Our model-based price target is the fair value of 3.16 TRY (as of Oct 30, 2026) from 7 valuation models. Cautious scenario 2.49 TRY, optimistic scenario 4.03 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Seyitler Kimya Sanayi AS stock forecast for 2026?
Our models put fair value at 3.16 TRY, about +32% upside versus a price of 2.39 TRY (undervalued). Cautious scenario 2.49 TRY, optimistic scenario 4.03 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of Seyitler Kimya Sanayi AS (SEYKM)?
Seyitler Kimya Sanayi AS reported trailing-twelve-month revenue of about 258M TRY (latest available figure, as of Oct 30, 2026).
What growth is priced into Seyitler Kimya Sanayi AS (SEYKM)?
For today's price to be fair in a discounted-cash-flow model, Seyitler Kimya Sanayi AS would have to grow free cash flow by -3.1 % per year for five years (discount rate 14.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +35.6 % per year. As of Oct 30, 2026.
What discount rate (WACC) does the fair value of SEYKM use?
Our models discount Seyitler Kimya Sanayi AS at 14.2 %: a base by market capitalisation (nano), damped by beta 1.01, country premium for Turkey. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Seyitler Kimya Sanayi AS that is -3.1 % per year a year over ten years, using the same discount rate (14.2 %) and the same formula as our fair value.
How much growth has Seyitler Kimya Sanayi AS (SEYKM) delivered so far?
Over the past 5 years revenue at Seyitler Kimya Sanayi AS grew +35.6 % a year. The price currently implies -3.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Seyitler Kimya Sanayi AS (SEYKM) growing?
The median revenue growth in the sector is +6.0 % a year. That is the yardstick for the growth priced into Seyitler Kimya Sanayi AS (-3.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Seyitler Kimya Sanayi AS (SEYKM)?
The free-cash-flow yield on the price is 15.07 %: that much free cash flow Seyitler Kimya Sanayi AS produces per unit of market value. When it exceeds the discount rate of our models (14.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Seyitler Kimya Sanayi AS (SEYKM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Seyitler Kimya Sanayi AS it is 3.16 TRY per share (as of Oct 30, 2026), against a price of 2.39 TRY. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Seyitler Kimya Sanayi AS stock overvalued or undervalued in 2026?
As of Oct 30, 2026, SEYKM trades below its calculated fair value: price 2.39 TRY, fair value 3.16 TRY, a gap of about +32% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SEYKM?
No. The price is what the market pays today (2.39 TRY); the fair value is what the company's own numbers justify (3.16 TRY). For Seyitler Kimya Sanayi AS the two are 0.7700 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Seyitler Kimya Sanayi AS worth?
The market values Seyitler Kimya Sanayi AS at about 478M TRY (market capitalisation, as of Oct 30, 2026). Per share that is 2.39 TRY; our models calculate a fair value of 3.16 TRY per share.
What do the bullish and bearish scenarios say about SEYKM?
Our models span a range for Seyitler Kimya Sanayi AS: cautious scenario 2.49 TRY, base 3.16 TRY, optimistic 4.03 TRY per share (as of Oct 30, 2026, price 2.39 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SEYKM?
Seyitler Kimya Sanayi AS trades at a price-to-earnings ratio of 17.1 (as of Oct 30, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 3.16 TRY is built from several models across several years. Other multiples: P/B 1.0, P/S 1.9.
How solid is the balance sheet of Seyitler Kimya Sanayi AS (SEYKM)?
Balance-sheet figures for Seyitler Kimya Sanayi AS (as of Oct 30, 2026): return on equity 4.4%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is SEYKM from its 52-week high?
Seyitler Kimya Sanayi AS trades at 2.39 TRY, about 65% below its 52-week high of 6.80 TRY and 1% above the low of 2.37 TRY (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of 3.16 TRY is for.
Which stocks are comparable to Seyitler Kimya Sanayi AS?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Seyitler Kimya Sanayi AS stock attractive at the current price?
The data as of Oct 30, 2026: price 2.39 TRY, calculated fair value 3.16 TRY (+32%), Quality Score 48/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SEYKM calculated?
We run Seyitler Kimya Sanayi AS through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3.16 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3 % above its aggregate fair value. Seyitler Kimya Sanayi AS currently trades 24 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Seyitler Kimya Sanayi AS (SEYKM)?
The closing price on Oct 30, 2026 was 2.39 TRY. Our model-based fair value is 3.16 TRY, about +32% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Seyitler Kimya Sanayi AS right now?
The price is below even our cautious bear case (2.49 TRY). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Seyitler Kimya Sanayi AS
How large is the market capitalisation of Seyitler Kimya Sanayi AS (SEYKM)?
The market capitalisation of Seyitler Kimya Sanayi AS is 478M TRY (≈ $9.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Seyitler Kimya Sanayi AS (SEYKM)?
The price-to-sales ratio of Seyitler Kimya Sanayi AS is 1.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Seyitler Kimya Sanayi AS (SEYKM)?
Earnings per share at Seyitler Kimya Sanayi AS are 0.1400 TRY (price ÷ EPS = P/E 17.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Seyitler Kimya Sanayi AS (SEYKM)?
The net margin of Seyitler Kimya Sanayi AS is 8.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Seyitler Kimya Sanayi AS (SEYKM)?
The return on equity (ROE) of Seyitler Kimya Sanayi AS is 4.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Seyitler Kimya Sanayi AS (SEYKM)?
On an EBIT basis the return on assets of Seyitler Kimya Sanayi AS is 3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Seyitler Kimya Sanayi AS (SEYKM)?
The operating margin of Seyitler Kimya Sanayi AS is −15.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Seyitler Kimya Sanayi AS (SEYKM)?
Revenue at Seyitler Kimya Sanayi AS is growing +10.8% versus a year earlier (3y avg +29.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Seyitler Kimya Sanayi AS (SEYKM)?
Earnings per share at Seyitler Kimya Sanayi AS are growing −14.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Seyitler Kimya Sanayi AS (SEYKM) carry?
The net debt of Seyitler Kimya Sanayi AS is 18.7M TRY (fiscal year 2023, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Seyitler Kimya Sanayi AS in the live analysis
One click puts Seyitler Kimya Sanayi AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 30, 2026